DUBLIN–(BUSINESS WIRE)–The “Global
Insomnia Treatment Market – Segmented by Treatment Type, Distribution
Channel, and Geography – Growth, Trends, and Forecast (2018 – 2023)”
report has been added to ResearchAndMarkets.com’s
The Insomnia Treatment Market is expected to grow at a CAGR of
approximately 5.5% during the forecast period.
The insomnia drugs comprise of a wide range of patented drugs as well as
generics. The patented drugs hold the larger share of the revenue in
developed regions due to better reimbursement policies. On the other
hand, generics & branded generics accounted for the largest revenue in
developing and underdeveloped regions.
Zolpidem is the highest selling insomnia treatment drug, owing to its
effectiveness and easy availability. In terms of sales channel
distribution, the prescription segment accounted for the largest share
of over 80% of the total market revenue in 2017. This segment is
expected to maintain its dominance throughout the forecast period owing
to an increase in the use of prescription pharmaceuticals.
Increasing Stress Due to the Highly Active Lifestyle of Individuals to
Induce a Surge in the Market
Patient Non-Adherence due to Characteristic Side Effects of Sleeping
Pills to Impede the Growth of the Market
- North America to Maintain the Lead as the Largest Shareholder
Major Developments in the Market
Cerve Inc., a privately-held healthcare company is preparing to launch
its FDA-cleared insomnia device. The company announced today the
closing of a $38 million Series B round of financing led by KKR, a
leading global investment firm. Also participating in the financing
are existing shareholders Versant Ventures, Arboretum Ventures, and
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players in Insomnia Treatment
- Ebb Therapeutics
- Merck & Co.
- Mylan N.V.
- Paratek Pharmaceuticals Inc.
- Pfizer Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co. Ltd.
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vanda Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/research/xlfbbc/global_insomnia?w=4
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Nervous System Drugs